Document Detail


N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: a pilot study.
MedLine Citation:
PMID:  8651965     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the efficacy and tolerability of N-[4 hydroxyphenyl] retinamide (4-HPR), a synthetic retinoid, in the treatment of rheumatoid arthritis (RA). METHODS: An uncontrolled, open clinical trial with synovial biopsy pre- and postmedication to evaluate the clinical effects of 4-HPR as well as its effects on metalloproteinase gene expression. RESULTS: Twelve patients with severe, longstanding RA were enrolled in this study. Six patients withdrew before study completion, 2 because of drug toxicity, 2 because of a flare of RA, and 2 because of intercurrent medical problems. No patient met predetermined Paulus criteria treatment response, and there was no improvement in the laboratory parameters, except for a modest decrease in C-reactive protein. No decrease in messenger RNA for the metalloproteinases collagenase and stromelysin was seen in the 2 patients in whom paired synovial biopsies were obtained. CONCLUSION: No beneficial clinical effect was observed with the retinoid 4-HPR in the treatment of severe, longstanding RA at the 300 mg/day dosage studied. The use of higher dosages is precluded by the observed toxicities. The effect of this drug in patients with early or mild disease was not studied. Although this particular retinoid was not effective in this pilot study, the use of other retinoids in RA should still be considered.
Authors:
E M Gravallese; M L Handel; J Coblyn; R J Anderson; R I Sperling; E W Karlson; A Maier; E M Ruderman; F Formelli; M E Weinblatt
Related Documents :
19933745 - Synovial immunopathology in haemochromatosis arthropathy.
1628165 - The effect of non-steroidal anti-inflammatory drugs on faecal flora and bacterial antib...
19509325 - Clinical implications of understanding radiographic findings in relation to clinical ou...
23978325 - High apolipoprotein e in cerebrospinal fluid of patients with lewy body disorders is as...
7772355 - Assessment of patient position for fiberoptic intubation using videolaryngoscopy.
10599835 - Galvanic stimulation in bilateral vestibular failure: 3-d ocular motor effects.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Arthritis and rheumatism     Volume:  39     ISSN:  0004-3591     ISO Abbreviation:  Arthritis Rheum.     Publication Date:  1996 Jun 
Date Detail:
Created Date:  1996-07-22     Completed Date:  1996-07-22     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0370605     Medline TA:  Arthritis Rheum     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1021-6     Citation Subset:  AIM; IM    
Affiliation:
St. Vincent's Hospital, Darlinghurst, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / administration & dosage*,  adverse effects,  pharmacology
Arthritis, Rheumatoid / complications,  drug therapy*
Collagenases / drug effects*,  metabolism
Drug Administration Schedule
Female
Fenretinide / administration & dosage*,  adverse effects,  pharmacology
Humans
Matrix Metalloproteinase 3
Metalloendopeptidases / drug effects*,  metabolism
Middle Aged
Pilot Projects
RNA, Messenger / drug effects*,  metabolism
Synovial Membrane / drug effects*,  enzymology
Treatment Outcome
Grant Support
ID/Acronym/Agency:
AI-07306/AI/NIAID NIH HHS; AR-01885/AR/NIAMS NIH HHS; AR-07530/AR/NIAMS NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/RNA, Messenger; 65646-68-6/Fenretinide; EC 3.4.24.-/Collagenases; EC 3.4.24.-/Metalloendopeptidases; EC 3.4.24.17/Matrix Metalloproteinase 3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving comb...
Next Document:  Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with...